title: Norcantharidin suppresses cell growth and migration with enhanced anticancer             activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
abstract: Norcantharidin is the demethylated analog of cantharidin isolated from blister             beetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidin             exhibits anticancer effects against the human non-small cell lung cancer cell             lines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9             (EGFR mutation-positive). Our results revealed that norcantharidin dose-dependently             retards cell growth, arrests cell cycle at G2/M phase, reduces cell migration,             and even induces apoptosis at the concentration of 100 µM. Moreover, we found             that norcantharidin enhances the anticancer effects of gefitinib and cisplatin.             Norcantharidin exhibited similar potency of anticancer effects against the two             cell lines with different EGFR mutation status and did not affect EGF-induced             EGFR phosphorylation, suggesting that the EGFR signaling may not be the target             of norcantharidin. In conclusion, our results suggest that norcantharidin exhibits             anticancer effects against non-small cell lung cancer cells in vitro and support             its potential as a chemotherapeutic agent for treating non-small cell lung cancer.
authors.affiliation: Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
authors.forename: Ya-Chun
authors.initials: YC
authors.lastname: Lee
authors.forename: Liang-Ming
authors.initials: LM
authors.lastname: Lee
authors.forename: Chih-Hsin
authors.initials: CH
authors.lastname: Yang
authors.forename: Anya Maan-Yuh
authors.initials: AM
authors.lastname: Lin
authors.forename: Yi-Chia
authors.initials: YC
authors.lastname: Huang
authors.forename: Chia-Chi
authors.initials: CC
authors.lastname: Hsu
authors.forename: Meng-Shian
authors.initials: MS
authors.lastname: Chen
authors.forename: Chin-Wen
authors.initials: CW
authors.lastname: Chi
authors.forename: Pen-Hui
authors.initials: PH
authors.lastname: Yin
authors.forename: Cheng-Deng
authors.initials: CD
authors.lastname: Kuo
authors.forename: Jyh-Fei
authors.initials: JF
authors.lastname: Liao
authors.forename: Hsin-Chen
authors.initials: HC
authors.lastname: Lee
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage; D004815:Epidermal Growth Factor / Q000494:pharmacology; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D009154:Mutation / Q000235:genetics; D010766:Phosphorylation / Q000187:drug effects; D011799:Quinazolines / Q000008:administration & dosage; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D011799:Quinazolines; D004815:Epidermal Growth Factor; C069741:norcantharidin; D066246:ErbB Receptors; D002945:Cisplatin; D000077156:Gefitinib